International scientific meetings:

In 2011, Dr. Novack was invited to speak on ophthalmic drug development on several international panels which included senior FDA ophthalmic personnel. These were:

• Ophthalmology Innovation Summit (Orlando, FL)
• Glaucoma sub-specialty day at the American Academy of Ophthalmology (Orlando, FL
• International Symposium on Ocular Pharmacology and Therapeutics (Vienna, Austria) www.isopt.net

He also participated in the first ophthalmology workshop of the European Medicines Agency (London, UK).

Regulatory consultancy:

Dr. Novack continued to work with numerous clients in providing regulatory guidance. In 2011, this included many meetings with FDA’s CDER to discuss the development of novel therapeutics.

Publications:

Among the many papers and abstracts published in 2011, Dr. Novack was an author on a Phase 2a study of a novel rho kinase inhibitor for the treatment of glaucoma:

Williams RD, Novack GD, van Haarlem T, Kopczynski C for the AR-12286 Phase 2a Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 2011:152: 834-841.

www.ajo.com

Dr. Novack selected for Glaucoma Society

Dr. Novack was selected as a member of the Glaucoma Research Society, a public interest, nonprofit scientific association of outstanding glaucoma researchers. The society provides a forum to discuss and stimulate compelling research to prevent glaucoma-related disability worldwide; the organization consists of fewer than 100 scientists whose investigations lead the field of glaucoma.